Pendapatan tahunan perusahaan Opthea Ltd (OPT)

Opthea Limited competes with market behemoths by offering a patented combination therapy for the treatment of macular degeneration. The company's revenue chart demonstrates fluctuations, where the 0.00 metric reflects current dynamics. Demand for ophthalmological drugs remains independent of economic cycles, while the business's financial standing currently relies on external investment, as the clinical trial stage does not yet generate operating income.

OPT: Pendapatan lan volume dodolan Opthea Corp 04.07.2022 - 28.06.2025

Rincian metrik komprehensif lan analitis Opthea (OPT)

- rega pasar lan target rega analis:

Rega bursa Opthea Corp|OPT - Bagan rega target

- rincian kapitalisasi pasar:

Biji pasar Opthea Limited|OPT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- rincian valuasi buku bisnis:

Rega Buku Saham Opthea|OPT - Kapitalisasi Buku|Nilai Pasar marang Nilai Buku opthea.com|OPT - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- informasi bathi lan kelipatan valuasi:

OPT - Bathi resik perusahaan|Bathi mangsa ngarep Opthea Limited|OPT - Pangali P/E|Kapitalisasi marang proyeksi bathi opthea.com|OPT - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Opthea Limited|OPT - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Opthea|OPT - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan opthea.com|OPT - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Opthea Limited

- statistik dodolan lan pendapatan perusahaan:

OPT - Pendapatan perusahaan|Pendapatan sing dikarepake perusahaan Opthea Corp|OPT - Kapitalisasi marang pendapatan|Rasio rega marang pendapatan sing dikarepake Opthea Limited

Analisis umum perusahaan:Opthea Corp - OPT

Opthea Limited is developing innovative biopharmaceuticals for the treatment of retinal pathologies, where the company's sales growth rate reflects the dynamics of actual cash inflows from product sales. This indicator captures daily revenue volume, allowing investors to objectively assess the stability of demand for sozinibercept and the commercial effectiveness of the VEGF-C/D pathway inhibition strategy amid market volatility.

Analisis perusahaan pesaing

Total pendapatan perusahaan Alcon Corp ALC|Pendapatan perusahaan Bausch + Lomb Corporation (BLCO)|GKOS: Pendapatan tahunan perusahaan|Apellis - Dodolan perusahaan|Total dodolan perusahaan BLTE (Belite Bio Corp)|Ocular Therapeutix Corp - Pendapatan lan volume dodolan|Pendapatan dodolan perusahaan HROW (Harrow Corp)|VRDN: Pendapatan lan volume dodolan|Total pendapatan perusahaan lenz-tx.com (LENZ)|OCS (Oculis Holding AG) - Pendapatan lan volume dodolan|Pendapatan lan volume dodolan EyePoint Pharmaceuticals Inc|Dodolan perusahaan KOD (Kodiak Pharma)|ALDX (aldeyra.com) - Pendapatan dodolan perusahaan|Pendapatan perusahaan KALA BIO KALA|Opus Genetics, Inc. - Pendapatan perusahaan|OKYO Pharma Inc - Pendapatan lan volume dodolan|Pendapatan reged perusahaan Adverum Biotechnologies ADVM|Outlook Pharma (OTLK) - Pendapatan perusahaan|Dodolan perusahaan Clearside Corp|NBY (NovaBay Pharmaceuticals Inc.) - Pendapatan lan volume dodolan|Kiora Pharma (KPRX) - Pendapatan reged perusahaan|Dodolan perusahaan ALIM (Alimera Sciences)|Total dodolan perusahaan EYEN|Pendapatan lan volume dodolan GHSI (Guardion Health Sciences Inc.)|Ocuphire Corporation (OCUP) - Total pendapatan perusahaan